Orbactiv (Oritavancin) for Skin Infections: Single-Dose MRSA Treatment Explained (FDA Approved 2014)
Quick answer: Orbactiv (oritavancin) is an intravenous lipoglycopeptide antibiotic that the U.S. Food and Drug Administration approved on August 6, 2014, for adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Its defining feature is that a full course is given as one infusion. The labeled dose is 1,200 mg IV over 3 hours. In the two phase 3 SOLO trials, which together enrolled about 1,987 adults, a single dose was noninferior to 7 to 10 days of vancomycin. A subset of 405 patients had documented MRSA infection. Orbactiv can interfere with coagulation tests and may affect warfarin, so patients on blood thinners need coordinated monitoring. Treatment decisions belong to your clinician.
Reading time: about 10 to 12 minutes. This article is educational and does not replace medical advice. Skin infections can spread, so contact a clinician promptly if redness, swelling, or fever develops.
Why Skin Infections Matter
Common and Sometimes Serious
Acute bacterial skin and skin structure infections include cellulitis, abscesses, and infected wounds. Many are mild, but some spread into deeper tissue or into the bloodstream and require prompt treatment.
MRSA and Access to Treatment
MRSA is a common cause of serious skin infection. Treating it often required IV vancomycin given every 12 hours for 7 to 10 days, which meant repeated infusions, drug-level monitoring, and sometimes hospital stays.
Why Single-Dose Options Are Valuable
A single infusion can reduce visits, support outpatient care, and make it easier for patients to complete treatment. Clinicians still weigh whether a single-dose drug is right for each infection.
Key Takeaways
- Orbactiv (oritavancin) received FDA approval on August 6, 2014, for adults with ABSSSI caused by susceptible gram-positive bacteria, including MRSA.
- The labeled dose is a single 1,200 mg IV infusion over 3 hours.
- In the SOLO I and SOLO II trials, about 1,987 adults received either oritavancin or 7 to 10 days of vancomycin. Oritavancin was noninferior, and 405 patients had documented MRSA.
- Oritavancin can interfere with coagulation tests and may affect warfarin, so patients on anticoagulants need coordinated monitoring.
- A newer formulation, Kimyrsa, was approved in March 2021 and is given over 1 hour.
- Coverage at approval reported no dose adjustment for mild or moderate kidney or liver dysfunction; confirm current guidance in the label.
What Is Orbactiv
Brand and Generic Names
Orbactiv is the brand name for oritavancin, originally developed by Targanta Therapeutics and later associated with The Medicines Company. Oritavancin is supplied as a powder that is reconstituted and given by intravenous infusion.
Drug Class
Oritavancin is a semi-synthetic lipoglycopeptide, related to vancomycin. It interferes with bacterial cell wall synthesis and has a distinct structure that gives it a long half-life, allowing single-dose therapy.
Dosage Form
Orbactiv is not a tablet. It is given in a clinic, infusion center, or hospital where staff monitor the infusion and watch for reactions.
FDA Approval: August 6, 2014
The Decision
The FDA approved Orbactiv on August 6, 2014, for adults with ABSSSI caused by susceptible designated gram-positive organisms, including MRSA. The approval was based on the SOLO I and SOLO II trials.
Positioning
The sponsor described Orbactiv as the first and only single-dose antibiotic for skin infections at the time of approval. Other antibiotics approved for ABSSSI in 2014 required multiple doses.
Outpatient Potential
The FDA and sponsor noted that a single infusion could allow treatment in an outpatient setting for infections likely caused by gram-positive organisms, including MRSA, subject to clinical judgment.
The Lipoglycopeptide Class
Relationship to Vancomycin
Lipoglycopeptides share a core structure with glycopeptides such as vancomycin, but they carry additional chemical groups. These groups improve binding to bacterial cell wall precursors and extend the drug's presence in the body.
Why the Class Matters
Lipoglycopeptides allow clinicians to treat serious gram-positive infections with fewer doses. Oritavancin and dalbavancin are the two long-acting lipoglycopeptides approved for skin infections in the United States.
Differences From Vancomycin
Vancomycin requires repeated dosing and drug-level monitoring. Oritavancin's long half-life allows a single dose, but it also means that any adverse effect or interaction may persist longer.
How Oritavancin Works
Cell Wall Synthesis
Oritavancin binds to the terminal D-alanyl-D-alanine residues of cell wall precursors and interferes with the transglycosylation and transpeptidation steps needed to build the cell wall. This leads to bacterial death.
Additional Mechanisms
Oritavancin has additional effects on bacterial membranes that may contribute to its activity against some resistant organisms. These details are part of the drug's pharmacology and are described in the prescribing information.
Persistence in the Body
Oritavancin binds tightly to plasma proteins and persists in tissues for a long time. This persistence supports the single-dose regimen but also means the drug is not quickly cleared if a reaction occurs.
Which Bacteria It Targets
Labeled Organisms
The labeled indication covers susceptible gram-positive organisms, including Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus group organisms. Confirm the full list in the current prescribing information.
Gram-Negative Organisms
Oritavancin is not used for gram-negative infections, which require different antibiotics.
Culture Guidance
Wound or abscess cultures help confirm the organism and its susceptibility pattern, guiding whether oritavancin is appropriate.
Approved Use and Labeling Limits
Who Is Eligible
The labeled population is adults with ABSSSI caused by susceptible gram-positive organisms. Pediatric use is outside the labeled indication.
Not Approved For
Orbactiv is not approved for bacteremia, endocarditis, osteomyelitis, or pneumonia as labeled indications. Use outside the label is a clinical decision for the treating team.
Stewardship Statement
The label emphasizes using antibiotics only for infections proven or strongly suspected to be caused by susceptible bacteria.
The SOLO Trials: Design
Overview
SOLO I and SOLO II were randomized, double-blind, multicenter phase 3 trials comparing a single 1,200 mg IV dose of oritavancin with 7 to 10 days of intravenous vancomycin in adults with ABSSSI.
Population
Together, the trials enrolled about 1,987 adults. A subset of 405 patients had documented MRSA infection, allowing a focused look at that population.
Primary Endpoint
The primary endpoint was early clinical response, based on lesion-size reduction and clinical assessment at a defined time after treatment began.
The SOLO Trials: Results
Noninferiority
A single dose of oritavancin was noninferior to 7 to 10 days of vancomycin for early clinical response. The FDA's approval rested on this finding.
Safety Summary
The most common adverse effects in the trials were headache, nausea, vomiting, and diarrhea. Most were mild to moderate in severity.
Reading the Numbers
Noninferiority means oritavancin performed about as well as the comparator within a prespecified margin. It does not prove superiority. Trial populations are selected, and real-world patients may differ.
The MRSA Subgroup
Why It Matters
MRSA is a central target for skin infection treatment. The 405 MRSA patients in the SOLO trials gave the FDA and clinicians a focused look at how oritavancin performs against this organism.
Interpretation
Subgroup analyses are smaller and less precise than the overall trial. They support the labeled use against MRSA, but they should be read as supportive evidence rather than a standalone proof for every patient.
Susceptibility Testing
Laboratory testing confirms whether a specific MRSA isolate is susceptible. Clinicians rely on this rather than assuming activity from the drug class.
Why a Single Dose Matters
Fewer Visits
A single infusion avoids the daily or twice-daily infusions required by vancomycin, which reduces visits and the burden of home infusion.
Support for Outpatient Care
Some patients who would otherwise need a longer hospital stay can be treated in an outpatient infusion setting, if their clinical condition allows.
Limits of the Single-Dose Approach
Once given, the drug remains in the body for a long time. If an adverse reaction occurs, it cannot be stopped quickly, and close observation during and after the infusion matters.
Dosing and Administration
Labeled Dose
The labeled regimen is a single 1,200 mg IV dose infused over 3 hours. Confirm the current dose and infusion instructions in the prescribing information on DailyMed.
Preparation
Pharmacists reconstitute and dilute the drug according to the label. Infusion rate and compatibility matter, so staff follow the instructions carefully.
Missed Doses
Because the regimen is a single dose, the main concern is ensuring that the infusion is completed. Patients should not try to repeat the dose on their own.
The Kimyrsa Formulation
What Changed
Kimyrsa, a newer oritavancin product, was approved in March 2021. It is given as a single dose over 1 hour, shorter than the original 3-hour infusion.
Why It Matters
A shorter infusion can reduce chair time and make treatment more convenient. Clinicians choose between the two products based on availability, cost, and institutional practice.
Confirm Your Product
If you are told you are receiving oritavancin, ask which formulation and infusion time apply to your dose.
Kidney and Liver Function
Kidney Function
Coverage at approval reported that no dose adjustment was needed for mild or moderate renal impairment. Kidney function still matters for overall care, so your team will monitor it.
Liver Function
Coverage at approval also reported no dose adjustment for mild or moderate hepatic dysfunction. Confirm guidance for more severe liver disease in the label.
Monitoring
Routine monitoring focuses on infection response and any side effects that appear after the infusion.
Common Side Effects
Most Frequent Effects
Headache, nausea, vomiting, and diarrhea were the most common adverse effects in the SOLO trials. Most were mild to moderate.
Infusion-Site Reactions
Pain, redness, or swelling at the IV site can occur. Nurses monitor the line and report any problems.
What to Report
Tell your care team about headache that is severe, persistent diarrhea, or any unusual bleeding or bruising.
Coagulation Test Interference
What Happens
Oritavancin can interfere with certain laboratory tests used to monitor blood clotting, including prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT). This can make these tests less accurate for a period after the dose.
Why It Matters
Clinicians rely on these tests to adjust anticoagulant therapy. If you are taking blood thinners, your team needs to know about the oritavancin dose so they can interpret results correctly.
Coordinate With Your Team
Tell your clinicians and laboratory staff when you received oritavancin. They may use alternative testing or adjust monitoring schedules.
Warfarin and Anticoagulant Interactions
Warfarin Effects
Oritavancin may affect warfarin metabolism, which can change how strongly the blood thinner works. The interaction is clinically important because warfarin doses are tightly managed.
Monitoring Plan
Patients on warfarin should have INR checked more often after receiving oritavancin, following the plan set by their care team. Do not change your warfarin dose on your own.
Other Anticoagulants
Heparin and other anticoagulants can also be affected by coagulation test interference. Your team will decide on the right monitoring approach.
Serious Risks and Warnings
Hypersensitivity Reactions
Serious allergic reactions can occur. Hives, facial swelling, trouble breathing, or fainting require emergency care. Tell your team about previous antibiotic reactions before treatment.
C. difficile Infection
C. difficile can cause severe diarrhea and colitis. Report any new or worsening diarrhea promptly, even weeks after treatment.
Bleeding Considerations
Because of coagulation test interference and warfarin interaction, patients with bleeding risk should be carefully evaluated before treatment.
Who Should Not Receive Orbactiv
Known Allergy
People with a known allergy to oritavancin, vancomycin, or other glycopeptides should not receive Orbactiv without specialist review.
Anticoagulated Patients
Patients on warfarin or other blood thinners need a coordinated monitoring plan, not automatic exclusion. The decision belongs to the care team.
Other Infections
Orbactiv is not approved for infections outside the labeled indication or for gram-negative organisms.
How Orbactiv Compares With Other Options
Vancomycin
Vancomycin was the comparator in SOLO. It requires repeated infusions and drug-level monitoring, while oritavancin is a single dose. Vancomycin remains a standard option for many serious infections.
Dalbavancin
Dalbavancin is another long-acting lipoglycopeptide approved for skin infections. It is typically given as one or two doses. Choice depends on the infection, cost, and local practice.
Linezolid and Tedizolid
Oral and IV oxazolidinones are alternatives for skin infections. Each has a different duration and safety profile, so the choice depends on the patient.
Outpatient Treatment and Follow-Up
Benefits
A single infusion can reduce visits and support outpatient care. Patients may return home the same day when clinically appropriate.
Limits
Because the drug stays in the body for a long time, clinics must be prepared to monitor and respond to reactions. Patients who do not improve need prompt reassessment.
Follow-Up Visits
Ask your team when to return, what symptoms should prompt an earlier visit, and whether blood tests are planned.
Antibiotic Stewardship
Use When Indicated
Many minor skin infections are managed with wound care and drainage. Antibiotics should be used when infection is proven or strongly suspected to be bacterial.
Culture Guidance
Cultures from wounds or abscesses guide whether oritavancin or another agent is appropriate.
Protecting the Drug
Overuse of any antibiotic increases resistance pressure. Responsible use helps keep oritavancin and related drugs effective.
Availability and Cost
Availability
Orbactiv and Kimyrsa are given in hospitals, clinics, and infusion centers. Availability depends on the facility, so your care team can confirm stock.
Cost
Oritavancin is a branded specialty antibiotic and is expensive. The single-dose regimen may reduce other costs, such as repeated infusions or hospital days. Ask your insurer or hospital financial counselor for current figures.
Coverage
Coverage for FDA-approved indications is generally more straightforward. Prior authorization may be required.
Pregnancy, Breastfeeding, and Children
Pregnancy
Pregnant patients with skin infections should discuss treatment options with their clinician. Decisions should weigh benefits against the limited data available.
Breastfeeding
Discuss breastfeeding with your care team before treatment.
Children
The labeled indication is for adults. Use in children is outside the labeled population and requires specialist judgment.
Questions to Ask Your Care Team
- Is my infection caused by a susceptible gram-positive organism, including MRSA?
- Am I taking warfarin or another blood thinner, and how will my INR be monitored?
- Which formulation and infusion time will I receive?
- Why is a single dose appropriate for my infection?
- What signs of spreading infection, bleeding, or diarrhea should I report right away?
Frequently Asked Questions
Q: What is Orbactiv used for?
A: It is approved for adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria, including MRSA.
Q: When was it approved?
A: The FDA approved it on August 6, 2014.
Q: Is it a single dose?
A: Yes. The labeled dose is one 1,200 mg IV infusion over 3 hours.
Q: How well did it work compared with vancomycin?
A: In the SOLO trials, a single dose was noninferior to 7 to 10 days of vancomycin for early clinical response.
Q: Does it interfere with blood thinners?
A: Yes. It can affect coagulation tests and may influence warfarin. Tell your team if you take a blood thinner.
Q: Is it a pill?
A: No. It is given only by IV infusion.
Q: What is Kimyrsa?
A: Kimyrsa is a newer oritavancin product approved in 2021 and given over 1 hour.
Medical Disclaimer
This article is for general education only and does not provide medical advice, diagnosis, or treatment. Skin infections can spread and require evaluation by a qualified clinician. Do not start, stop, or change any antibiotic or blood thinner without guidance from your care team. For dosing, warnings, and interactions, consult the current U.S. prescribing information on DailyMed. If you have spreading redness, fever with chills, rapid heartbeat, unusual bleeding, or trouble breathing, seek emergency care immediately.
Sources and Further Reading
- The Medicines Company press release on FDA approval of Orbactiv, August 6, 2014
- Emergency Medicine and NEJM Journal Watch coverage of the FDA approval of oritavancin, August 2014
- SOLO I and SOLO II trial publications, including Corey et al., New England Journal of Medicine, 2014
- Drugs.com Kimyrsa FDA approval history (approval March 12 or 15, 2021, depending on source)
- Orbactiv and Kimyrsa U.S. Prescribing Information, including dosing, warnings, and coagulation test interference
This article reflects information available as of October 2026. Confirm current prescribing details with your healthcare provider and the latest FDA labeling. For more on MyOnlineMedShop, visit our blog or contact us.
